Screener
Gyre Therapeutics, Inc. GYRE Total Operating Expenses
Discontinued — last reported Q3 '23
Total Operating Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed October 26, 2023.
- Filed
- Oct 26, 2023
- Fiscal quarter
- Q3 FY2023
- Calendar quarter
- Q3 2023
- Accession
- 0000950170-23-055695
| Line item | Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 |
|---|---|---|---|---|
| General and administrative | 2,408 | 4,363 | 8,603 | 13,201 |
| GNI cost-sharing reimbursement | (1,200) | — | (1,200) | — |
| Gain on disposal of assets, net | — | — | (4,736) | (57,245) |
| Total operating expenses (income) | 1,623 | 5,166 | 3,988 | (30,869) |
| Income (loss) from operations | (1,623) | (5,166) | (3,988) | 31,663 |
| Interest and other income, net | 47 | 282 | 216 | 549 |
| Income (loss) before income taxes | (1,576) | (4,884) | (3,772) | 32,212 |
| Income tax expenses | — | — | 16 | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s total operating expenses?
- Gyre Therapeutics, Inc. (GYRE) reported total operating expenses of $1.62M in Q3 2023.
- How has Gyre Therapeutics, Inc.'s total operating expenses changed year-over-year?
- Gyre Therapeutics, Inc.'s total operating expenses decreased by 68.6% year-over-year, from $5.17M to $1.62M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Gyre Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude